The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Messenger RNA Vaccines and Therapeutics Market 2024 by Company, Regions, Type and Application, Forecast to 2029

Global Messenger RNA Vaccines and Therapeutics Market 2024 by Company, Regions, Type and Application, Forecast to 2029

Publishing Date : Jul, 2023

License Type :
 

Report Code : 1751021

No of Pages : 102

Ask Your Query

Synopsis
The global Messenger RNA Vaccines and Therapeutics market size was valued at USD 10080 million in 2022 and is forecast to a readjusted size of USD 22370 million by 2029 with a CAGR of 12.1% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

An mRNA vaccine is a vaccine that uses a molecular copy of messenger RNA to generate an immune response. [1] Such vaccines deliver antigen-coding mRNA molecules into immune cells, which use the designed mRNA as a template to build foreign proteins normally produced by pathogens such as viruses or cancer cells. These protein molecules stimulate an adaptive immune response, teaching the body to recognize and destroy the corresponding pathogen or cancer cell. mRNA is composed of RNA encapsulated in lipid nanoparticles, which protect the RNA strand and facilitate its uptake into cells. Reactogenicity, the propensity of the vaccine to produce adverse reactions, was similar to that of traditional non-RNA vaccines. People prone to autoimmune reactions may experience adverse reactions to messenger RNA vaccines. Compared with traditional vaccines, mRNA vaccines have the advantages of being easy to design, fast in production, low in cost, capable of inducing cellular and humoral immunity, and not interacting with genomic DNA.

This report is a detailed and comprehensive analysis for global Messenger RNA Vaccines and Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

  • Global Messenger RNA Vaccines and Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029
  • Global Messenger RNA Vaccines and Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
  • Global Messenger RNA Vaccines and Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
  • Global Messenger RNA Vaccines and Therapeutics market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

  • To determine the size of the total market opportunity of global and key countries
  • To assess the growth potential for Messenger RNA Vaccines and Therapeutics
  • To forecast future growth in each product and end-use market
  • To assess competitive factors affecting the marketplace

This report profiles key players in the global Messenger RNA Vaccines and Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include BioNTech, Moderna, CureVac, Pfizer and Glaxo Smith Kline's, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation

Messenger RNA Vaccines and Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

  • Self-amplifying
  • Conventional Non-amplifying

Market segment by Application

  • Cancer
  • Infectious Diseases
  • Autoimmune Diseases
  • Others

Market segment by players, this report covers

  • BioNTech
  • Moderna
  • CureVac
  • Pfizer
  • Glaxo Smith Kline's
  • Daiichi Sankyo Company
  • Intellia Therapeutics
  • Arcturus Therapeutics
  • Emmy Vaccine
  • CSPC
  • CanSino
  • Fosun Pharma

Market segment by regions, regional analysis covers

  • North America (United States, Canada, and Mexico)
  • Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
  • South America (Brazil, Argentina and Rest of South America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Messenger RNA Vaccines and Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Messenger RNA Vaccines and Therapeutics, with revenue, gross margin and global market share of Messenger RNA Vaccines and Therapeutics from 2018 to 2023.
Chapter 3, the Messenger RNA Vaccines and Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Messenger RNA Vaccines and Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Messenger RNA Vaccines and Therapeutics.
Chapter 13, to describe Messenger RNA Vaccines and Therapeutics research findings and conclusion.

Index

1 Market Overview
1.1 Product Overview and Scope of Messenger RNA Vaccines and Therapeutics
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Messenger RNA Vaccines and Therapeutics by Type
1.3.1 Overview: Global Messenger RNA Vaccines and Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Type in 2022
1.3.3 Self-amplifying
1.3.4 Conventional Non-amplifying
1.4 Global Messenger RNA Vaccines and Therapeutics Market by Application
1.4.1 Overview: Global Messenger RNA Vaccines and Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Cancer
1.4.3 Infectious Diseases
1.4.4 Autoimmune Diseases
1.4.5 Others
1.5 Global Messenger RNA Vaccines and Therapeutics Market Size & Forecast
1.6 Global Messenger RNA Vaccines and Therapeutics Market Size and Forecast by Region
1.6.1 Global Messenger RNA Vaccines and Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Messenger RNA Vaccines and Therapeutics Market Size by Region, (2018-2029)
1.6.3 North America Messenger RNA Vaccines and Therapeutics Market Size and Prospect (2018-2029)
1.6.4 Europe Messenger RNA Vaccines and Therapeutics Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Messenger RNA Vaccines and Therapeutics Market Size and Prospect (2018-2029)
1.6.6 South America Messenger RNA Vaccines and Therapeutics Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Messenger RNA Vaccines and Therapeutics Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 BioNTech
2.1.1 BioNTech Details
2.1.2 BioNTech Major Business
2.1.3 BioNTech Messenger RNA Vaccines and Therapeutics Product and Solutions
2.1.4 BioNTech Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 BioNTech Recent Developments and Future Plans
2.2 Moderna
2.2.1 Moderna Details
2.2.2 Moderna Major Business
2.2.3 Moderna Messenger RNA Vaccines and Therapeutics Product and Solutions
2.2.4 Moderna Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Moderna Recent Developments and Future Plans
2.3 CureVac
2.3.1 CureVac Details
2.3.2 CureVac Major Business
2.3.3 CureVac Messenger RNA Vaccines and Therapeutics Product and Solutions
2.3.4 CureVac Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 CureVac Recent Developments and Future Plans
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Messenger RNA Vaccines and Therapeutics Product and Solutions
2.4.4 Pfizer Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Pfizer Recent Developments and Future Plans
2.5 Glaxo Smith Kline's
2.5.1 Glaxo Smith Kline's Details
2.5.2 Glaxo Smith Kline's Major Business
2.5.3 Glaxo Smith Kline's Messenger RNA Vaccines and Therapeutics Product and Solutions
2.5.4 Glaxo Smith Kline's Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Glaxo Smith Kline's Recent Developments and Future Plans
2.6 Daiichi Sankyo Company
2.6.1 Daiichi Sankyo Company Details
2.6.2 Daiichi Sankyo Company Major Business
2.6.3 Daiichi Sankyo Company Messenger RNA Vaccines and Therapeutics Product and Solutions
2.6.4 Daiichi Sankyo Company Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Daiichi Sankyo Company Recent Developments and Future Plans
2.7 Intellia Therapeutics
2.7.1 Intellia Therapeutics Details
2.7.2 Intellia Therapeutics Major Business
2.7.3 Intellia Therapeutics Messenger RNA Vaccines and Therapeutics Product and Solutions
2.7.4 Intellia Therapeutics Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Intellia Therapeutics Recent Developments and Future Plans
2.8 Arcturus Therapeutics
2.8.1 Arcturus Therapeutics Details
2.8.2 Arcturus Therapeutics Major Business
2.8.3 Arcturus Therapeutics Messenger RNA Vaccines and Therapeutics Product and Solutions
2.8.4 Arcturus Therapeutics Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Arcturus Therapeutics Recent Developments and Future Plans
2.9 Emmy Vaccine
2.9.1 Emmy Vaccine Details
2.9.2 Emmy Vaccine Major Business
2.9.3 Emmy Vaccine Messenger RNA Vaccines and Therapeutics Product and Solutions
2.9.4 Emmy Vaccine Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Emmy Vaccine Recent Developments and Future Plans
2.10 CSPC
2.10.1 CSPC Details
2.10.2 CSPC Major Business
2.10.3 CSPC Messenger RNA Vaccines and Therapeutics Product and Solutions
2.10.4 CSPC Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 CSPC Recent Developments and Future Plans
2.11 CanSino
2.11.1 CanSino Details
2.11.2 CanSino Major Business
2.11.3 CanSino Messenger RNA Vaccines and Therapeutics Product and Solutions
2.11.4 CanSino Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.11.5 CanSino Recent Developments and Future Plans
2.12 Fosun Pharma
2.12.1 Fosun Pharma Details
2.12.2 Fosun Pharma Major Business
2.12.3 Fosun Pharma Messenger RNA Vaccines and Therapeutics Product and Solutions
2.12.4 Fosun Pharma Messenger RNA Vaccines and Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
2.12.5 Fosun Pharma Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Messenger RNA Vaccines and Therapeutics Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Messenger RNA Vaccines and Therapeutics by Company Revenue
3.2.2 Top 3 Messenger RNA Vaccines and Therapeutics Players Market Share in 2022
3.2.3 Top 6 Messenger RNA Vaccines and Therapeutics Players Market Share in 2022
3.3 Messenger RNA Vaccines and Therapeutics Market: Overall Company Footprint Analysis
3.3.1 Messenger RNA Vaccines and Therapeutics Market: Region Footprint
3.3.2 Messenger RNA Vaccines and Therapeutics Market: Company Product Type Footprint
3.3.3 Messenger RNA Vaccines and Therapeutics Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global Messenger RNA Vaccines and Therapeutics Consumption Value and Market Share by Type (2018-2023)
4.2 Global Messenger RNA Vaccines and Therapeutics Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global Messenger RNA Vaccines and Therapeutics Consumption Value Market Share by Application (2018-2023)
5.2 Global Messenger RNA Vaccines and Therapeutics Market Forecast by Application (2024-2029)
6 North America
6.1 North America Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2029)
6.2 North America Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2029)
6.3 North America Messenger RNA Vaccines and Therapeutics Market Size by Country
6.3.1 North America Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2029)
6.3.2 United States Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
6.3.3 Canada Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
6.3.4 Mexico Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2029)
7.2 Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2029)
7.3 Europe Messenger RNA Vaccines and Therapeutics Market Size by Country
7.3.1 Europe Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2029)
7.3.2 Germany Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
7.3.3 France Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
7.3.5 Russia Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
7.3.6 Italy Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Messenger RNA Vaccines and Therapeutics Market Size by Region
8.3.1 Asia-Pacific Messenger RNA Vaccines and Therapeutics Consumption Value by Region (2018-2029)
8.3.2 China Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8.3.3 Japan Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8.3.4 South Korea Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8.3.5 India Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
8.3.7 Australia Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
9 South America
9.1 South America Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2029)
9.2 South America Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2029)
9.3 South America Messenger RNA Vaccines and Therapeutics Market Size by Country
9.3.1 South America Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2029)
9.3.2 Brazil Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
9.3.3 Argentina Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Messenger RNA Vaccines and Therapeutics Market Size by Country
10.3.1 Middle East & Africa Messenger RNA Vaccines and Therapeutics Consumption Value by Country (2018-2029)
10.3.2 Turkey Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
10.3.4 UAE Messenger RNA Vaccines and Therapeutics Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 Messenger RNA Vaccines and Therapeutics Market Drivers
11.2 Messenger RNA Vaccines and Therapeutics Market Restraints
11.3 Messenger RNA Vaccines and Therapeutics Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 Messenger RNA Vaccines and Therapeutics Industry Chain
12.2 Messenger RNA Vaccines and Therapeutics Upstream Analysis
12.3 Messenger RNA Vaccines and Therapeutics Midstream Analysis
12.4 Messenger RNA Vaccines and Therapeutics Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer

Published By : GlobalInfoResearch

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock